Mindray Updates on New Products - Analyst Blog
22 Luglio 2011 - 1:15PM
Zacks
Mindray Medical
International Limited (MR), a leading Chinese medical
device company, recently disclosed updates for its product launches
in the first half of the current fiscal year. A spokesperson for
the company stated that Mindray is on target to introduce 7 to 10
new products during 2011.
During the first half, the company
launched four products in its three segments. The newly introduced
products include a defibrillator (BeneHeart D3), an advanced auto
hematology analyzer (BC-6800), an anesthesia machine (A5 Anesthesia
System) and a black and white portable ultrasound system
(DP-50).
The BeneHeart D3
Defibrillator/Monitor is a light, durable and compact defibrillator
that integrates manual defibrillation, monitoring, pacing and other
functions. Among the different features, its vital signs monitoring
function of ECG and respiration can improve efficiency of
diagnosis. BC-6800 Auto Hematology Analyzer is a sophisticated
automatic hematology analyzer with solid processing speed. A5
Anesthesia System is the first of Mindray’s latest series of
anesthesia machines incorporating advanced design features.
DP-50 Digital Portable Ultrasound
System is an ultrasound system with better mobility, sleek design
and easier operation well-suited for clinical settings. The DP-50
incorporates advanced features that produce higher resolution and
greater penetration.
Mindray is a bellwether in the
Chinese MedTech industry with a solid international presence. It
operates in three segments: Patient Monitoring, In-vitro
Diagnostics and Medical Imaging. A key distinction with domestic
competitors is that the majority of Mindray’s products have CE Mark
and/or Food and Drug Administration (“FDA”) clearance.
Mindray’s first-quarter 2011
earnings per share of 32 cents missed the Zacks Consensus Estimate
by a couple of cents. The company generated total revenues of
$180.9 million in the quarter, up 24% year over year, of which
domestic sales contributed $72.5 million.
Mindray maintains a decent product
pipeline and brings out several new products each year. New
products contribute in a major way to Mindray’s revenues.
Mindray’s competitors, in different
niche segments, include General Electric (GE),
Philips (PHG) and Siemens (SI).
Our long-term Neutral rating on the stock is supported by a
short-term Zacks #3 Rank.
GENL ELECTRIC (GE): Free Stock Analysis Report
MINDRAY MEDICAL (MR): Free Stock Analysis Report
KONINKLIJKE PHL (PHG): Free Stock Analysis Report
SIEMENS AG-ADR (SI): Free Stock Analysis Report
Zacks Investment Research
Grafico Azioni Montage Resources (NYSE:MR)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Montage Resources (NYSE:MR)
Storico
Da Lug 2023 a Lug 2024